Compositions and methods of regulating glucose homeostasis and insulin action

Patent metadata

Field	Value
Publication number	US-10683306-B2
Application number	US-201916387268-A
Country	US
Kind code	B2
Filing date	Apr 17, 2019
Priority date	Jun 20, 2012
Publication date	Jun 16, 2020
Grant date	Jun 16, 2020

Abstract

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15 ((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.

First claim

What is claimed is:

1. A method for treating hyperinsulinemia, hyperlipidemia, glycemia, glucose tolerance, insulin sensitivity, adiposity, insulin resistance, obesity, or diabetes in a subject, said method comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier, optionally at least one additional therapeutic agent, and an effective amount of at least one compound having a structure of Formula I or Formula II:

wherein R 1 -R 10 are all independently optional, and are each independently selected from the group consisting of H, halogen, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfone, sulfoxide, oxo, oxy, nitro, carbonyl, carboxy, amino acid sidechain, and amino acid, wherein each group can be optionally substituted, or a pharmaceutically acceptable salt or

wherein R 1 -R 2 are independently optional, and are each independently selected from the group consisting of H, halogen, hydroxy, acyl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo, aryl, heteroaryl, alkoxy, amino, amide, thiol, sulfone, sulfoxide, oxo, oxy, nitro, carbonyl, carboxy, amino acid sidechain, and amino acid, wherein each group can be optionally substituted, or a pharmaceutically acceptable salt.

2. The method of claim 1 , wherein said compound is a mitochondrial uncoupler.

3. The method of claim 1 , wherein the method is a method for treating diabetes and said diabetes is type II diabetes.

4. A method for treating hyperinsulinemia, glycemia, glucose tolerance, insulin sensitivity, adiposity, insulin resistance, obesity, or diabetes in a subject, said method comprising administering to a subject a compound or pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:

5. The method of claim 4 , wherein said compound is administered at a dosage ranging from about 0.1 mg/kg to about 50 mg/kg body weight.

6. The method of claim 5 , wherein said compound is administered at a dosage ranging from about 0.5 mg/kg to about 25 mg/kg body weight.

7. The method of claim 6 , wherein said compound is administered at a dosage ranging from about 1.0 mg/kg to about 5.0 mg/kg body weight.

8. The method of claim 4 , wherein said compound is BAM15:

9. The method of claim 1 , wherein the method is a method for treating adiposity and the subject is a human.

10. The method of claim 1 , wherein the method is a method for treating obesity and the subject is a human.

11. The method of claim 1 , wherein the method is a method for treating diabetes and the subject is a human.

12. The method of claim 8 , wherein the method is a method for treating adiposity and the subject is a human.

13. The method of claim 8 , wherein the method is a method for treating obesity and the subject is a human.

14. The method of claim 8 , wherein the method is a method for treating diabetes and the subject is a human.

15. The method of claim 1 , wherein the method is a method for treating adiposity and the subject is an animal.

16. The method of claim 1 , wherein the method is a method for treating obesity and the subject is an animal.

17. The method of claim 1 , wherein the method is a method for treating diabetes and the subject is an animal.

18. The method of claim 8 , wherein the method is a method for treating adiposity and the subject is an animal.

19. The method of claim 8 , wherein the method is a method for treating obesity and the subject is an animal.

20. The method of claim 8 , wherein the method is a method for treating diabetes and the subject is an animal.

Assignees

• Univ Virginia
• Univ Virginia Patent Foundation

Inventors

• Hoehn Kyle
• Kenwood Brandon

Classifications

• G01N2500/10

  involving cells · CPC title

• A61K31/4985

  Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title